CEDAR KNOLLS, N.J.,
May 27, 2020 /PRNewswire/ -- MYOS
RENS Technology Inc. ("MYOS" or "the Company") (NASDAQ: MYOS), a
bionutrition company and the owner of
Fortetropin®, a proprietary bioactive composition
made from fertilized egg yolk that helps build lean muscle,
announced today that it has entered into a distribution agreement
with BodyLogicMD, a leading physician-owned
network of anti-aging medical practices located throughout
the United States.
MYOS and BodyLogicMD have developed a private-label,
Fortetropin-based nutrition product, BodyLogicMD Muscle
Formula, that will be distributed across BodyLogicMD's
nationwide network of anti-aging medical practices.
Headquartered in Boca Raton,
Florida, BodyLogicMD's network is comprised of nearly 65
affiliated anti-aging medical practitioners in more than 45
franchise practices spread across 28 states. BodyLogicMD is a
member of the American Academy of Anti-Aging Medicine (A4M) and
requires all of its network physicians to be trained and certified
through the A4M Fellowship in Anti-Aging and Regenerative
Medicine.
"We are absolutely delighted to be partnering with BodyLogicMD
to distribute BodyLogicMD Muscle
Formula. MYOS has worked with a range of health
care professionals to formulate products that address their
specific client's needs with our clinically proven muscle building
ingredient, Fortetropin. The BodyLogicMD network is a premier
nationwide network for anti-aging medicine and hormone replacement
therapy," stated Joseph Mannello,
CEO of MYOS.
"We believe that many patients visiting anti-aging physicians
can benefit from the Fortetropin-based product, BodyLogicMD
Muscle Formula. Extensive research at leading academic
institutes has shown that muscle mass and longevity are correlated.
Fortetropin helps alleviate age-related muscle loss," added Mr.
Mannello.
"We are very excited about working with MYOS to bring
BodyLogicMD Muscle Formula to market. We are
truly impressed with the quality and degree of preclinical and
human clinical research that has been conducted on
Fortetropin. Very few nutrition products have been studied to
this degree. It has become clear in recent years that muscle health
is an area of medicine that is underappreciated. Addressing
muscle health through a combination of diet and exercise can help
patients improve their quality of life and longevity. We look
forward to a highly fruitful and successful partnership with MYOS,"
commented Jennifer Landa, M.D.,
Chief Medical Officer of BodyLogicMD.
On March 11, 2020, Professor
William Evans, University of California, Berkeley presented
results from a randomized, double blind, placebo-controlled human
clinical trial that examined the impact of Fortetropin on the rate
of muscle protein synthesis in older men and women (60-75 years of
age) at the International Conference on Frailty &
Sarcopenia Research in Toulouse,
France (https://frailty-sarcopenia.com/). The results
indicated that subjects who consumed Fortetropin on a daily basis
experienced an increased rate of muscle protein synthesis of
approximately 15% when compared with subjects who were given a
macronutrient-matched placebo.
About MYOS RENS Technology Inc.
MYOS RENS Technology
Inc. (MYOS), "The Muscle Company®", is a Cedar Knolls, NJ-based advanced nutrition
company that develops and markets products that improve muscle
health and performance. MYOS developed and introduced
Fortetropin®, a fertilized egg yolk-based product
manufactured via a proprietary process to retain and optimize its
biological activity. Fortetropin has been clinically shown to
increase muscle size, lean body mass and reduce muscle atrophy.
MYOS believes Fortetropin has the potential to redefine existing
standards of physical health and wellness. MYOS has worked with a
range of health care professionals to formulate and distribute
products addressing clients' specific needs. The private label
products incorporate the Company's key active ingredient,
Fortetropin, known for its muscle building properties. For more
information, please visit www.myosrens.com.
About BodyLogicMD.
Founded in 2003, BodyLogicMD
physician-owned practices make up the nation's largest and fastest
growing network of highly-trained practitioners specializing in
bioidentical hormone replacement therapy. Integrated with
comprehensive wellness strategies, BodyLogicMD's
medically-supervised treatment plans are for men and women
suffering from hormonal imbalance and conditions of aging, such as
menopause and andropause. Headquartered in Boca Raton, FL, the BodyLogicMD network is
comprised of nearly 65 affiliated practitioners operating in more
than 45 franchise practices spread across 28 states. BodyLogicMD is
a member of the American Academy of Anti-Aging Medicine (A4M) and
requires all practitioners in the network to be trained and
certified through the A4M Fellowship in Anti-Aging and Regenerative
Medicine. BodyLogicMD partners with leading laboratories,
compounding pharmacies, and nutraceutical producers to deliver the
highest quality products and services to network practitioners and
their patients.
Forward-Looking Statements
Any statements in this release that are not historical facts
are forward-looking statements. Actual results may differ
materially from those projected or implied in any forward-looking
statements. Such statements involve risks and uncertainties,
including but not limited to those relating to product and customer
demand, market acceptance of our products, the ability to create
new products through research and development, the successful
results of strategic initiatives, the success of our products,
including BodyLogicMD Muscle Formula, Physician Muscle
Health Formula®, Yolked®, MYOS
Canine Muscle Formula®, Qurr®, and
MYOS Enteral Nutrition Formula™, the success of
our research and development, the results of the clinical
evaluation of Fortetropin® and its
effects, our ability to enter into new distribution partnership
opportunities and the success of our existing partnerships, the
ability to enter into new distribution agreements such as the one
described in this release, the ability to generate revenue and cash
flow from sales of our products, the ability to increase our
revenue and gross profit margins, the ability to achieve a
sustainable, profitable business, the effect of economic
conditions, the ability to protect our intellectual property
rights, competition from other providers and products, the
continued listing of our securities on the Nasdaq Stock
Market, risks in product development, our ability to raise capital
to fund continuing operations, the adverse impact of the COVID-19
pandemic on the economy and our business, and other factors
discussed from time to time in our filings with the Securities and
Exchange Commission. We undertake no obligation to update or revise
any forward-looking statement for events or circumstances after the
date on which such statement is made except as required by
law.
Investor Relations:
MYOS RENS Technology
Joanne Goodford
Phone: 973-509-0444
Email: jgoodford@myoscorp.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/myos-announces-distribution-agreement-with-bodylogicmd-a-leading-nationwide-network-of-anti-aging-medical-practices-301065717.html
SOURCE MYOS RENS Technology